Detecting CTE in the brains of living individuals could improve our understanding of the disease and inform research regarding prevention and treatment.
For male patients with Parkinson disease, sexual activity is associated with lower motor and nonmotor disability.
Neurocrine Biosciences announced that the Food and Drug Administration has accepted the New Drug Application for opicapone.
The FDA has granted Fast Track designation to PR001 (Prevail Therapeutics) for the treatment of Parkinson disease patients with a GBA1 mutation (PD-GBA).
In patients with Parkinson disease who receive subthalamic nucleus deep brain stimulation, suicide behaviors tend to occur during the first 3 years after the procedure.
Researchers find caudate quantification of DAT availability shortly after diagnosis may have an important role in identifying patients at risk for clinical progression to cognitive impairment, depression, and gait problems in the near future.
International Parkinson’s and Movement Disorder Society released recommendations on clinical screening instruments and rating scales used to measure impulsive and compulsive behaviors in Parkinson disease.
Investigators sought to determine the risk for Parkinson disease development in patients with hepatitis C virus who received antiviral treatment and in patients who did not receive this treatment.
More frequent manic/mixed and depressive episodes were associated with an increased risk for Parkinson disease.
For older patients with blood cancers, gait speed can identify frailty and predict outcomes.